An extended release pharmaceutical dosage form comprising a Solid mixture in the form of an extended release Matrix formulation, where the mixture comprises at least: (1) at least one Poly (- Caprolactone), and (2) at least one polyethylene oxide, and (3) at least one Agent And active.Claim 1: a Solid pharmaceutical dosage form comprising an extended release, mix in the form of an extended release Matrix formulation, where the mixture comprises at least: (1) at least one Poly (- Caprolactone) with an average Molecular Weight from approximately And About 10000 to about 200.000, and (2) at least one polyethylene oxide with an average Molecular Weight of approximately around 10000 to less than 1000000, and (3) at least one ACTIVE AGENT. Claim 62: the form of extended release Solid pharmaceutical dosage according to any one of claims 1 to 61, where the extended release Matrix formulation comprising at least one additional retardant.Claim: the pharmaceutical Solid dosage form of extended release claims 64, where the flame is behenato Glyceryl.Claim 76: the form of extended release Solid pharmaceutical dosage according to claim 75, the opioid Analgesic is selected from the group consisting of codeine, morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, salts, hydrates, solvates and me The previous zclas pharmaceutically acceptable.Claim: The 92 Pharmaceutical Solid dosage form of extended release according to claims 91, where opioid antagonist is selected from the group consisting of naloxone, naltrexone and nalmefene, salts, hydrates, solvates and pharmaceutically acceptable to the mixtures Nteriores.Una forma de dosis farmacéutica de liberación extendida sólida, que comprende una mezcla en la forma de una formulación matricial de liberación extendida, donde la mezcla comprende al menos: (1) al menos una poli(e-caprolactona), y (2) al menos un óxido de polietileno, y (3) al menos un agente activo. Reivindicación 1: Una forma de dosis farmacéutica sólida de libe
